Research location

Würzburg

Germany

Published trials379

Site observations393

Linked trials published379

Page1 / 8

Research activity in Würzburg

Germany

CureCurrent currently publishes aggregate city-level research activity for this location: 379 trials and 393 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Würzburg

379 linked trials · page 1 of 8

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)NCT07492680 · 2026-07-27 · 1 site observation

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CMNCT07690436 · 2026-07-08 · 1 site observation

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMNCT07667803 · 2026-06-29 · 1 site observation

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 · 2026-05-11 · 1 site observation

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)NCT07611110 · 2026-05-04 · 1 site observation

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)NCT07531095 · 2026-04-21 · 1 site observation

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsNCT07195695 · 2026-01-16 · 1 site observation

A Study of AZD0120 in Autoimmune DiseasesNCT07295847 · 2026-01-09 · 1 site observation

An Open-label Study of AZD0120 in Adults With Multiple SclerosisNCT07224373 · 2025-12-09 · 1 site observation

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28 · 1 site observation

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)NCT06996782 · 2025-11-24 · 1 site observation

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseNCT07174310 · 2025-11-24 · 1 site observation

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyNCT07472517 · 2025-11-07 · 1 site observation

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24 · 1 site observation

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)NCT06855771 · 2025-09-09 · 1 site observation

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationNCT06952803 · 2025-08-06 · 1 site observation

Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)NCT07067437 · 2025-07-01 · 1 site observation

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 InflammationNCT06959095 · 2025-06-20 · 1 site observation

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)NCT06875310 · 2025-04-24 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · 2025-04-10 · 1 site observation

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647 · 2024-11-27 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)NCT06692738 · 2024-11-18 · 1 site observation

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)NCT06598306 · 2024-10-07 · 1 site observation

Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControlNCT06498349 · 2024-09-05 · 1 site observation

STIMPulseControl Ancillary Speech StudyNCT06561919 · 2024-09-05 · 1 site observation

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)NCT06274801 · 2024-09-03 · 1 site observation

Liquid Biopsy Under PSMA Radioligand TherapyNCT07118436 · 2024-09-01 · 1 site observation

A Non-interventional, Prospective Study With BenralizumabNCT06422078 · 2024-07-25 · 1 site observation

Impact of a High-fiber Diet on the Microbiome and Disease Activity in Patients With Rheumatoid ArthritisNCT06492200 · 2024-06-01 · 1 site observation

Corheart 6 LVAS StudyNCT05876000 · 2024-05-14 · 1 site observation

Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNSNCT06553625 · 2024-01-29 · 1 site observation

KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410 · 2023-10-18 · 1 site observation

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab DeruxtecanNCT05573893 · 2023-09-12 · 1 site observation

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)NCT06311708 · 2023-01-31 · 1 site observation

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerNCT05498428 · 2022-11-11 · 1 site observation

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709 · 2021-05-27 · 1 site observation

COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast CancerNCT05906407 · 2019-04-19 · 1 site observation

Deep Brain Stimulation (DBS) Retrospective Outcomes StudyNCT03664609 · 2019-03-12 · 1 site observation

CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast CancerNCT05652569 · 2017-06-12 · 1 site observation

The European NAFLD RegistryNCT04442334 · 2015-05-01 · 1 site observation

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS RegistryNCT02071134 · 2014-03-04 · 1 site observation

A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNCT07861100 · 2026-10-26 · 1 site observation

NOT_YET_RECRUITING

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471 · 2025-09-15 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)NCT07005128 · 2025-08-18 · 1 site observation

ACTIVE_NOT_RECRUITING

ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsNCT06973161 · 2025-06-10 · 1 site observation

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerNCT06764485 · 2025-03-13 · 1 site observation

ACTIVE_NOT_RECRUITING

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLCNCT06745323 · 2025-02-26 · 1 site observation

ACTIVE_NOT_RECRUITING

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984 · 2024-12-09 · 1 site observation

ACTIVE_NOT_RECRUITING

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.